Endocrinology

ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.

Semaglutide significantly reduced risk of a first-time diagnosis of AD in a cohort of more than 1 million, suggesting an opportunity for controlled clinical trials.

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Three-quarters of primary care survey respondents prescribe GLP-1 RAs for weight loss and half get questions daily about the drugs. See all the results.

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

Bayer announced 12 presentations focused on symptoms of menopause and effects of its investigational oral nonhormonal medication elinzanetant.

Antiobesity medications are the next step after lifestyle interventions prove inadequate; here are the American Gastroenterological Association recommendations, at-a-glance.

Update: The FDA has told compounding pharmacies they may resume production of tirzepatide products while the agency further investigates supply.

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.

The elinzanetant NDA is based on data, including long-term efficacy, from the OASIS phase 3 clinical trial program, according to Bayer.

Obesity is a complex disease that requires a multispecialty approach to address the physical and also the mental and emotional components of the widespread disorder.

Your daily dose of the clinical news you may have missed.

The risk of gestational diabetes was 2-fold greater among young women with prediabetes before conceiving compared with those who had normoglycemia.

Find details on advances in the management of type 1 diabetes, utilization of CGM in primary care settings, and optimizing T2D management in older persons.

The only CGM system cleared for 1 year of use in type 1 and 2 diabetes is expected to be available in the fourth quarter of this year, the manufacturers said.

Your daily dose of the clinical news you may have missed.

EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.

Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Type 2 diabetes and prediabetes were associated with accelerated brain aging, particularly among men and persons with poor cardiometabolic health, according to new research.